tiprankstipranks
Advertisement
Advertisement

VERA Stock Latest News

Vera Therapeutics Announces New Chief Regulatory Officer
Company AnnouncementsVera Therapeutics Announces New Chief Regulatory Officer
12d ago
8K
VERA
Vera chief regulatory officer William Turner to retire, Nancy Boman to succeed
PremiumThe Fly
Vera chief regulatory officer William Turner to retire, Nancy Boman to succeed
12d ago
KYTX
VERA
Vera Therapeutics price target raised to $76 from $56 at Guggenheim
PremiumThe Fly
Vera Therapeutics price target raised to $76 from $56 at Guggenheim
13d ago
VERA
Vera Therapeutics price target raised to $78 from $73 at TD Cowen
PremiumThe Fly
Vera Therapeutics price target raised to $78 from $73 at TD Cowen
13d ago
VERA
Vera Therapeutics price target raised to $43 from $35 at Wedbush
PremiumThe Fly
Vera Therapeutics price target raised to $43 from $35 at Wedbush
13d ago
VERA
FDA Approval and Extended Exclusivity of Trutakna Drive Vamil Divan to Reiterate Buy on Vera and Raise Price Target from $56 to $76
PremiumRatingsFDA Approval and Extended Exclusivity of Trutakna Drive Vamil Divan to Reiterate Buy on Vera and Raise Price Target from $56 to $76
13d ago
VERA
Vera Therapeutics price target raised to $125 from $110 at H.C. Wainwright
Premium
The Fly
Vera Therapeutics price target raised to $125 from $110 at H.C. Wainwright
13d ago
VERA
Maintaining a Buy on Vera: Commercial-Stage Transition and Trutakna Strength Support Unchanged $90 Price Target
Premium
Ratings
Maintaining a Buy on Vera: Commercial-Stage Transition and Trutakna Strength Support Unchanged $90 Price Target
14d ago
VERA
Vera Therapeutics price target raised to $70 from $65 at BofA
PremiumThe Fly
Vera Therapeutics price target raised to $70 from $65 at BofA
14d ago
VERA
Vera Therapeutics gains FDA nod for TRUTAKNA launch
PremiumCompany Announcements
Vera Therapeutics gains FDA nod for TRUTAKNA launch
14d ago
8K
VERA
Vera’s Trutakna approved by FDA for adults with primary IgA nephropathy
PremiumThe Fly
Vera’s Trutakna approved by FDA for adults with primary IgA nephropathy
14d ago
VERA
Vera Therapeutics announces alignment with FDA on earlier ORIGIN 3 eGFR analysis
PremiumThe Fly
Vera Therapeutics announces alignment with FDA on earlier ORIGIN 3 eGFR analysis
2M ago
VERA
Raymond James sees unique buying opportunity in Vera after FDA alignment
PremiumThe FlyRaymond James sees unique buying opportunity in Vera after FDA alignment
2M ago
VERA
Vera Therapeutics: Buy Rating Reiterated as Atacicept’s Regulatory Path Advances; $90 Price Target Maintained
Premium
Ratings
Vera Therapeutics: Buy Rating Reiterated as Atacicept’s Regulatory Path Advances; $90 Price Target Maintained
2M ago
VERA
Vera Therapeutics Advances Atacicept Approval Path in IgA Nephropathy
Premium
Company Announcements
Vera Therapeutics Advances Atacicept Approval Path in IgA Nephropathy
2M ago
8K
VERA
Vera Therapeutics Stockholders Back Board, Governance Proposals
PremiumCompany Announcements
Vera Therapeutics Stockholders Back Board, Governance Proposals
2M ago
8K
VERA
Vera Therapeutics price target lowered to $91 from $95 at Evercore ISI
PremiumThe Fly
Vera Therapeutics price target lowered to $91 from $95 at Evercore ISI
2M ago
VERA
Analyst Reiterates Buy on Vera as Atacicept Progress and Strong Cash Position Support Unchanged $110 Price Target
PremiumRatings
Analyst Reiterates Buy on Vera as Atacicept Progress and Strong Cash Position Support Unchanged $110 Price Target
2M ago
VERA
Vera Therapeutics: Buy Rating Reiterated on Strong Atacicept Outlook and Launch Readiness; $73 Price Target Maintained
PremiumRatings
Vera Therapeutics: Buy Rating Reiterated on Strong Atacicept Outlook and Launch Readiness; $73 Price Target Maintained
2M ago
VERA
Vera Therapeutics reports Q1 EPS ($1.69), consensus ($1.37)
PremiumThe FlyVera Therapeutics reports Q1 EPS ($1.69), consensus ($1.37)
3M ago
VERA
Vera Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research
Premium
The Fly
Vera Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research
4M ago
VERA
VRTX
Vertex poses ‘no threat’ to Vera Therapeutics’ atacicept, says BofA
Premium
The Fly
Vertex poses ‘no threat’ to Vera Therapeutics’ atacicept, says BofA
4M ago
VERA
VRTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >